LC-Fatty Acid Oxidation Disorders: Recent Updates on the REN001 Study
There was much discussion about current research in FAODs at the 2022 International Metabolic conference. Reneo Pharmaceuticals recently released positive results from the REN001 Phase1b LC-FAOD Study.
Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals will provide background about the Reneo LC-FAOD clinical study and answer questions.
Date: 08/18/2022Listen Now: Click Here
Related Articles
MELAS Spectrum Disorders and Sonlicromanol: Progress Update
Date: 03/18/2022Speaker:
Dr. Jan Smeitink